Magnilife Psoriasis Care NDC 43689-0036

NDC codes

FDA NDC Directory

Product NDC (as listed)43689-0036Labeler and product segments. Claims need a package NDC.

Product NDC at billing width43689-0036Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
43689-0036-2	43689003602	1 JAR in 1 BOTTLE, UNIT-DOSE (43689-0036-2) / 56 g in 1 JARMarketed from Jun 29, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Magnilife Psoriasis Care
Generic name (nonproprietary): graphite, daphne mezereum bark,
Active ingredients: Graphite — 3 [hp_X]/gDaphne mezereum bark — 6 [hp_X]/g
Dosage form: Cream
Route: Topical
Labeler: The Magni Group, Inc.
Product type: Over-the-counter drug
Marketing category: Unapproved homeopathic
Marketing start: Jun 29, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 43689-0036_55916b33-840a-ef74-e063-6294a90af75fSPL ID 55916b33-840a-ef74-e063-6294a90af75fSPL set ID 7460dbd4-7322-43eb-aad7-7d1482f41435UNII 4QQN74LH4O, X2N6E405GVUPC 0723122170542

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N443689003602 followed by a unit qualifier and the quantity

Package 43689-0036-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 1, 2026.

Indications (excerpt from the label)

Uses For temporary relief of painful, itchy, dry and scaly skin

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)